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Short Abstract 
A rapid bacterial pellet preparation from a positive blood culture can be used as a 
sample for  applications such as identification by MALDI-TOF, Gram staining, antibiotic 
susceptibility testing and PCR-based  test. The results can be rapidly communicated to 
clinicians to improve the outcome of patients suffering from bloodstream infections. 
Long Abstract 
	  
Bloodstream infections and sepsis are a major cause of morbidity and mortality. The 
successful outcome of patients suffering from bacteremia depends on a rapid 
identification of the infectious agent to guide optimal antibiotic treatment. The analysis of 
Gram stains from positive blood culture can be rapidly conducted and already 
significantly impact the antibiotic regimen. However, the accurate identification of the 
infectious agent is still required to establish the optimal targeted treatment. We present 
here a simple and fast bacterial pellet preparation from a positive blood culture that can 
be used as a sample for several essential downstream applications such as 
identification by MALDI-TOF MS, antibiotic susceptibility testing (AST) by disc diffusion 
assay or automated AST systems and by automated PCR-based diagnostic testing. The 
performance of these different identification and AST systems applied directly on the 
blood culture bacterial pellets is very similar to the performance normally obtained from 
isolated colonies grown on agar plates. Compared to conventional approaches, the 
rapid acquisition of a bacterial pellet significantly reduces the time to report both 
identification and AST. Thus, following blood culture positivity, identification by MALDI-
TOF can be reported within less than an hour whereas results of AST by automated 
AST systems or disc diffusion assays within 8 to 18 hours, respectively. Similarly, the 
results of a rapid PCR-based assay can be communicated to the clinicians less than 2 
hours following the report of a bacteremia. Together, these results demonstrate that the 
rapid preparation of a blood culture bacterial pellet has a significant impact on the 
identification and AST turnaround time and thus on the successful outcome of patients 
suffering from bloodstream infections. 
    
Introduction 
 
Bloodstream infections and sepsis in hospitalized patients are a major cause of 
morbidity and mortality. Thus, mortality related to bloodstream infections is observed in 
about 14% to 37 % of hospitalized patient and may increase to 35% in intensive care 
units patients 1-3. The rapid identification of the infectious agent is pivotal to guide 
optimal antimicrobial treatment and to increase the successful outcome of antimicrobial 
therapy. The rapid analysis of Gram stains from positive blood culture has already a 
significant impact on the adaptation of antimicrobial therapy 4,5 but accurate identification 
of the infectious agent is required to provide the best adapted antibiotic treatment to the 
patients. For instance, different antibiotic treatment regimens have to be implemented 
following bacteremia with enterococci and streptococci that are difficult to distinguish by 
Gram staining. Similarly, identification at the species level is required to detect Gram 
negative enterobacteria encoding a chromosomal ampC gene which confer an 
increased resistance to β-lactams 6. 
With a positive blood culture, the conventional diagnostic approach is to subculture the 
infectious agent on different agar plates, which requires several hours of additional 
incubation prior identification with various approaches including biochemical tests, 
growth on different selective media and automated microbial identification systems. The 
time to results of a conventional diagnostic approach is of about 1 to 3 days.  
The emergence of the matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF) technology for rapid identification of microorganisms has 
provided a new tool to quickly identify microorganisms from colonies grown on agar 
plates but also directly from positive blood cultures (Figure 1) 7-10. The use of MALDI-
TOF to identify an infectious agent from blood cultures has significantly reduced the time 
to results to a few minutes instead of the hours and days required by traditional 
methods. As discussed by Croxatto et al. 11, the efficiency of MALDI-TOF identification 
relies on different parameters including the microorganism’s purity and quantity. These 
two criteria are easily obtained from discrete colonies grown on agar plates but required 
a pre-analytical treatment for bacterial enrichment and purification from complex 
samples such as blood culture, which contain multiple cellular and protein components 
that may interfere with MALDI-TOF identification.  
Various microorganisms’ isolation methods from blood culture have been used in a 
number of studies including saponin or other mild detergents method for bacterial 
extraction 7,12, serum separator method 8, lysis centrifugation methods 10 and 
commercially solutions such as the Sepsityper kit (Bruker Daltonics, Bremen, Germany). 
Our bacteriology diagnostic laboratory has developed a simple blood-culture bacterial 
pellet preparation based on ammonium chloride erythrocyte-lysis which allow fast 
identification of bacteria and yeast by MALDI-TOF and automated identification systems 
(Figure 2) 13. This blood-culture pellet preparation also provide a sample for other direct 
downstream applications such as Gram staining, automated PCR-based diagnostic tests 
such as POCT-PCRs for the rapid detection of methicillin-resistant Staphyloccocus 
aureus (MRSA), and antibiotic susceptibility testing with automated AST systems and/or 
by disk diffusion assays on agar plates (Figure 3). 
In this work, we describe the different steps for the preparation of the blood-culture 
bacterial pellet (Figure 4). We will also describe the protocols for three of the main 
applications that can be performed on the blood culture pellet: Identification by MALDI-
TOF 13, identification (ID) and antibiotic susceptibility testing (AST) with the automated 
systems 14 for Enterobacteriaceae and staphylococci and automated PCR-based 
diagnostic test for the detection of MRSA 15. 
Protocols 
This protocol has been developed and validated following the research and development 
processes and ethical rules of our institution before being implemented as a routine tool. 
1. Preparation of a blood culture bacterial pellet by ammonium chloride erythrocyte-
lysing procedure 
1.1. Preparation of a positive blood culture for subsequent centrifugation. 
1.1.1. Sterilize the blood culture cap. Add 70 % ethanol on the cap of the bottle and burn it. 
Do not perform this step under a laminar flow hood. 
1.1.2. Move the bottle to a laminar flow hood. Collect 5 ml of the blood culture with a 20 
needle gauge syringe 
1.1.3. Add the 5 ml of blood culture in a 50 ml Falcon tube containing 45 ml of sterile water 
(H2O) and mix the sample. 
1.2. Preparation of a blood culture bacterial pellet by lysis centrifugation. 
1.2.1. Centrifuge the sample at 1000 x g for 10 min at room temperature. 
1.2.2. Remove the supernatant (which contains mainly H20 and blood cells) with a 
laboratory vacuum pump. 
1.2.3. Resuspend the pellet in 1 ml of home-made ammonium chloride lysing solution 
(0.15M NH4Cl, 1mM KHCO3). Break down the pellet by scraping and by vortexing the tube 
and centrifuge the sample at 140 x g for 10 min at room temperature. 
1.2.4. Discard the supernatant which mainly contains red blood cells debris. 
1.2.4.1. If the pellet remained hemorrhagic, resuspend the pellet in 2 ml of sterile and distilled 
H20 to further lyse residual red blood cells and to wash the pellet. Centrifuge the sample at 
140 x g for 10 min at room temperature and discard the supernatant.  
1.2.5. Resuspend the pellet in 200 µl of H2O 
1.3. Subculture of blood culture on various selective and non selective agar media. 
1.3.1. Collect 1 ml of the blood culture with a 20 needle gauge syringe. 
1.3.2. Inoculate 1 drop of blood culture into four quadrants on blood agar, chocolate agar, 
McConkey agar and Schaedler agar. 
1.3.3. Incubate at 37°C the blood agar and chocolate agar plates in a 5% CO2 atmosphere, 
the McConkey agar in a normal atmosphere and the Schaedler agar plate in anaerobic 
conditions.  
1.3.4. Follow bacterial growth on the different media. 
1.3.5. Check for bacterial purity. 
 This protocol has been developed and validated following the research and development 
processes and ethical rules of our institution before being implemented as a routine tool. 
2. Identification by MALDI-TOF MS 
2.1. Direct identification from the blood pellet. 
2.1.1. Transfer 1 µl of the blood pellet on a MALDI target plate and let it dry on a 42°C 
heating platform. 
2.1.2. Overlay the sample with 1µl 70% formic acid and let it dry on a 42°C heating platform. 
2.1.3. Overlay the sample with 1µl of MALDI matrix (saturated solution of a-cyano-4-
hydroxycinnamic acid in 50% acetonitrile-2.5% trifluoroacetic acid) and let it dry on a 42°C 
heating platform. 
2.1.4. Proceed to MALDI-TOF MS analysis with a MALDI-TOF MS system as described by 
the manufacturers. 
2.1.5. If the identification score is invalid at the species level (for instance with a score < 2), 
perform a protein extraction of the blood pellet sample. 
2.2. Identification after protein extraction from the blood culture pellet. 
2.2.1. Mix 20 µl of the pellet with 1ml of 70% ethanol and centrifuge at 13’000 x g for 2 min 
at room temperature. 
2.2.2. Discard the supernatant and add 25 µl of 70% formic acid and 25 µl of 100% 
acetonitrile to the pellet. Vortex vigorously to resuspend properly the pellet. Difficult to 
resuspend pellets can be broken down with pipette tips before vortexing. 
2.2.3. Centrifuge at 13’000 x g for 2 min at room temperature. Transfer 1 µl of the 
supernatant (which contain extracted proteins) on a MALDI target plate and let it dry on a 
42°C heating platform. Proceed as described in 2.1.2 
This protocol has been developed and validated following the research and development 
processes and ethical rules of our institution before being implemented as a routine tool. 
3. Bacterial identification and antibiotic susceptibility testing with an automated 
system. 
3.1. Preparation of a bacterial suspension for bacterial identification and AST with an 
automated system. 
3.1.1. Prepare a plastic tube containing 3ml of sterile 0.45 % NaCl solution compatible with 
the automated system. 
3.1.2. Add a sufficient volume of the blood culture pellet in the 0.45 % NaCl solution to 
obtain a bacterial suspension corresponding to a McFarland turbidity of 0.6 to 0.8 measured 
with a densitometer machine. The volume of the blood culture bacterial pellet required to 
achieve a McFarland turbidity of 0.6 to 0.8 is highly variable but is usually comprised between 
50 to 200 µl. 
3.2. Inoculate the automated Gram-positive (GP) or Gram-negative (GN) cards for 
identification (this step is not applied if MALDI-TOF MS identification gave a score value >2) 
and the automated AST cards for antimicrobial susceptibility testing of Gram-positive cocci 
and Gram-negative bacteria as described by the manufacturer. 
3.3. Subculture the bacterial suspension on blood agar (GP and GN) and MacConkey agar 
(GN) plates to check the purity of the bacterial suspension. 
This protocol has been developed and validated following the research and development 
processes and ethical rules of our institution before being implemented as a routine tool. 
4.  Antibiotic susceptibility testing by disk diffusion assay as described by the 
European committee on antimicrobial susceptibility testing (EUCAST, Version 3.0, 
April 2013, www.eucast.org) 
4.1. Preparation of a bacterial suspension to perform antimicrobial susceptibility 
testing by disk diffusion assay. 
4.1.1. Prepare a glass tube containing 3ml of sterile 0.9 % NaCl solution. 
4.1.2. Add a sufficient volume of the blood culture pellet in the 0.9 % NaCl solution to obtain 
a bacterial suspension corresponding to a McFarland turbidity of 0.5 measured with a 
densitometer machine. The volume of the blood culture bacterial pellet required to achieve a 
McFarland turbidity of 0.5 is highly variable but is usually comprised between 50 to 200 µl. 
4.1.3. Vortex the bacterial suspension 
4.2. Inoculation of bacterial suspension onto Mueller-Hinton agar (MH) or Mueller-
Hinton agar-fastidious organisms agar (MHF) (MH supplemented with 5% defibrinated 
horse blood and 20 mg/L of β-Nicotinamide adenine dinucleotide).  
4.2.1.  Dip a sterile cotton swab in the bacterial suspension and gently remove excess fluid 
by turning the swab on the inside wall of the glass tube. 
4.2.2. Spread the bacterial suspension evenly onto the entire surface of the MH/MHF agar 
plate by swabbing in three directions or by using an automated plate rotator. 
4.3. Application of antimicrobial disks on inoculated agar plates. 
4.3.1. Apply closely the disks on the surface of the dried inoculated agar plates manually or 
by using a susceptibility disk dispenser. 
4.3.2. Incubate the plate at the appropriate temperature and atmosphere as described in the 
antimicrobial susceptibility testing EUCAST disk diffusion method (Version 3.0, April 2013, 
www.eucast.org). 
This protocol has been developed and validated following the research and development 
processes and ethical rules of our institution before being implemented as a routine tool. 
5. Automated PCR-based diagnostic test for the detection of MRSA  
5.1. Using a micropipette, transfer 50 µl of the blood culture pellet into the sample reagent 
vial provided with the MRSA automated PCR-based diagnostic test kit and vortex during 20 
seconds 
5.2. Using a 1ml micropipette, dispense the sample into the specimen port of the cartridge. 
Insert the cartridge into the automated PCR system and start the assay as described by the 
manufacturer. 
 
Representative results 
	  
In the study performed by Prod’hom et al. 13, bacterial pellets obtained by ammonium chloride 
lysis centrifugation of 122 positive blood culture from 78 patients were analyzed by MALDI-
TOF MS. Out of 122 positive blood culture, 95 (77.9%) were correctly identified at the species 
level and one (0.8%) at the genus level. The remaining 26 (21.3%) blood culture pellets gave 
no reliable identification by MALDI-TOF. Among those, 21 were gram positive bacteria 
including 13 streptococci and 5 coagulase-negative staphylococci. Importantly, 10 out of the 
13 unidentified streptococci were Streptococcus pneumoniae which often possess a difficult-
to-lyse capsule and are hardly distinguished from species of the S. mitis group using MALDI-
TOF MS. Five Gram-negative bacteria were not identified by MALDI-TOF, among which four 
difficult-to-lyse encapsulated bacterial species including two Klebsiella pneumoniae and two 
Haemophilus influenzae. Thus, correct identification by MALDI-TOF was obtained in 78.7 % 
of blood culture pellets, which represents an efficient performance compared to the 84.1% of 
identification obtained from conventional identification of bacterial colonies grown on agar 
plates 9. 
The performance of the automated Vitek 2 system for bacterial identification (ID) and for AST 
was tested on 278 bacterial pellets of positive blood culture for Gram-positive cocci in cluster 
and Gram-negative bacteria. These results were compared to conventional results obtained 
with the Vitek 2 cards from colonies grown on agar plates following subculture of positive 
blood culture on appropriate media 14. Direct identification using Vitek 2 cards can be used 
when identification of the bacterial pellet by MALDI-TOF MS has failed. Compared to a final 
identification by MALDI-TOF MS, a correct identification with Vitek 2 ID cards was observed in 
99% of Enterobacteriaceae, 74% of staphylococci, 71% of non-fermentative Gram-negative 
bacteria and 13% of other Gram-positive cocci. A misidentification was observed in 11% of 
total cases whereas 8% of bacterial pellets gave no identification. A total of 220 bacterial 
pellets including 87 Enterobacteriaceae and 133 staphylococci were analyzed for AST with 
Vitek 2 AST GN26 and AST 580 cards 14. The results were analyzed according to definitions 
given by the US Food and Drug Administration (FDA) for interpretive agreement results, 
which defined a false susceptible as a very major error (VME) and a false resistant as a major 
error (ME). AST obtained from direct inoculation of blood culture pellet compared to 
inoculation from colonies grown on agar plates showed 0.1% VME and 0.3% ME for 
Enterobacteriaceae, and 0.7% VME and 0.1% ME for staphylococci. Thus the performance of 
Vitek 2 AST cards inoculated directly with blood culture pellets are in agreement with the 
performance criteria accepted by the FDA. 
The performance of the PCR-based GeneXpert MRSA test targeting the spa, mecA and SCC 
genes was directly applied on Staphylococcus aureus blood culture bacterial pellets identified 
by MALDI-TOF MS 15. Based on 106 cases, the detection of methicillin resistance with the 
GeneXpert MRSA exhibited a 99% sensitivity and a 100% specificity. Interestingly, the 
median time to report the GeneXpert results from blood culture positivity was equal to 201 
min (range 100-430) whereas the median time from MALDI-TOF identification to report of the 
GeneXpert results was equal to 97 min (range 25-250). 
Figures 
	  
Figure 1: Pre- and post-MALDI-TOF era. Compared to conventional diagnostic approaches 
which include an overnight subculture of the sample, MALDI-TOF MS identification can be 
performed within minutes following samples delivery to the diagnostic laboratory. 	  
Figure 2: Workflow of blood culture processing from sampling to MALDI-TOF MS 
identification. When blood cultures are positive, a bacterial pellet is prepared by ammonium 
chloride lysis centrifugation. This bacterial pellet is then used for direct identification by 
MALDI-TOF MS. MALDI-TOF MS identification can be obtained within 30 to 60 min following 
blood culture positivity.  
Figure 3: Many downstream applications including Gram staining, MALDI-TOF MS 
identification, AST using automated systems and/or disk diffusion assays and rapid PCR-
based testing such as point of care testing PCRs (POCT-PCR)for the detection of MRSA can 
be performed directly on the blood culture bacterial pellet. Direct testing from the bacterial 
blood culture pellets significantly decrease the turn-around time to report ID and AST results 
which is pivotal to improve the outcome of patients suffering from bloodstream infections.  
Figure 4: The ammonium chloride lysis centrifugation protocol allows the preparation of an 
enriched and purified bacterial pellet from positive blood culture broths. Gram staining of 
positive blood culture of Escherichia coli, coagulase-negative Staphylococcus capitis and 
Streptococcus dysgalactiae performed before and after the preparation of the blood culture 
bacterial pellet. The classical morphologies of staphylococci in clusters and streptococci in 
chains are more easily observed in the native blood culture broth than in the blood culture 
bacterial pellet. Scale bar = 25 µm 
Discussion 
	  
Compared to conventional positive blood culture diagnostic approaches, the rapid acquisition 
of a bacterial pellet by using the ammonium chloride lysis centrifugation approach reduce the 
time to report identification by 16 to 24 hours and the time to report AST by 24 to 48 hours 
(Figure 1 to 3). 
Rapid introduction of appropriate antibiotic therapy is pivotal to improve the outcome of 
patients suffering from bloodstream infections. Thus, early identification of the infectious 
agents within an hour followed by a rapid AST obtained in about 8 to 16 hours represents a 
major impact in the clinical management of septic patients. The rapid reporting of Gram 
staining has already been associated with a great impact on antimicrobial therapy and thus 
with a decrease in patient morbidity and mortality 4,5. The Gram staining of the blood culture 
bacterial pellet may be done to increase sensitivity when the Gram staining of the blood 
culture broth is negative or weakly positive (Figure 4). However, Gram staining performed on 
the native blood culture broth is recommended to observe typical morphologies such as 
staphylococci in clusters or streptococci in chains.  In a recent prospective study performed 
on 202 cases of bloodstream infection, MALDI-TOF MS identification from blood culture 
pellets showed an impact in antibiotic therapy in 35.1% of cases whereas Gram stain had 
only an additional impact in 20% of cases 6. Interestingly, the maximum difference of impact 
between Gram staining and MALDI-TOF MS identification reporting on clinical management 
was observed when bacteria associated with increased antibiotic resistance such as AmpC-
producing Enterobacteriaceae were identified by MALDI-TOF MS.  Moreover, the use of a 
rapid PCR-based assay such as the GeneXpert MRSA following S. aureus identification by 
MALDI-TOF MS from blood culture pellets allowed to provide the most appropriate antibiotic 
therapy in less than 4 hours to patients suffering from S. aureus bacteremia 15. When 
excluding patients with penicillin allergy, the use of the GeneXpert MRSA allowed a significant 
reduction of anti-MRSA antibiotics misuse such as glycopeptides from 26.1% to 8.1%. 
Together, these data suggest that rapid sequential reporting of Gram staining, MALDI-TOF 
MS identification and rapid PCR-based assay from blood culture pellets are significantly 
improving the antibiotic therapy and thus the clinical management as well as the outcome of 
patients suffering from bloodstream infections. 
MALDI-TOF MS allowed a 78.7% correct identification of blood culture pellets, which is a very 
good performance compared to a rate of 84.1% identification obtained by conventional 
MALDI-TOF MS performed on pure colonies grown on agar plates. More that 50% of 
bloodstream infections are caused by bacterial species such as Enterobacteriaceae, 
Staphylococcus aureus, Pseudomonas aeruginosa and enterococci. These bacteria are 
efficiently identified by MALDI-TOF MS which likely positively influence the good performance 
of MALDI-TOF MS identification performed directly on blood culture bacterial pellets. The low 
performance for the identification of some bacterial species by MALDI-TOF MS performed on 
blood culture pellets is mainly due to similar factors than those observed for the conventional 
identification from pure colonies grown on agar plates. For instance, several microbial species 
such as Streptococci belonging to the mitis group and coagulase-negative staphylococci are 
closely related and identified with low accuracy by MALDI-TOF MS. Moreover, a particular 
composition of the bacterial cell wall of Gram-positive bacteria or the presence of a dense 
capsule observed in bacterial species such as Klebsiella pneumoniae significantly decrease 
the lysis efficiency and thus the performance of MALDI-TOF MS identification. Finally, the low 
performance of MALDI-TOF MS for the identification of anaerobic bacteria is mainly due to an 
incomplete and poor representation of these bacteria in the MALDI-TOF database.  
The small reduced performance of MALDI-TOF MS identification from blood culture pellets 
compared to conventional identification from pure colonies may be due to residual blood 
protein components or to an insufficient amount of bacteria obtained after lysis-centrifugation. 
Similarly, the differences observed with the Vitek 2 cards inoculated directly with blood culture 
pellets compared to those inoculated with isolated colonies may be caused by residual blood 
culture components such as proteins, blood cells and blood medium compounds that may 
interfere with bacterial growth in the Vitek 2 cards and may have a significant impact on both 
identification and AST. Moreover, the AST results obtained by Vitek 2 systems need to be 
checked by disk diffusion assays also performed directly on blood culture bacterial pellets to 
validate the results of some antibiotics known to present significant discrepancies compared 
to conventional approaches. However, direct inoculation of the Vitek 2 cards with blood 
culture pellets presents an excellent ID and AST performance for both Enterobacteriaceae 
and staphylococci. 
Thus, the bacterial pellet obtained by ammonium chloride lysis centrifugation of positive blood 
cultures has been validated to directly perform several downstream applications allowing a 
rapid reporting of essential results such as ID and AST in a significantly reduced TAT 
compared to conventional approaches. Moreover, additional applications such as extended-
spectrum β-lactamases (ESBLs) testing have been validated on similar lysis centrifugation of 
positive blood culture methodologies 16 suggesting that they could also be applied on the 
bacterial pellet obtained with the protocol described in this work.  
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Name of reagent /equipment Company
20 needle gauge Terumo, Leuven, Belgium
Ammonium chlorure Merck, Darmstadt, Germany
Potassium hydrogen carbonate Fluka, St. Louis, MO 
Formic acid Sigma-Aldrich, St. Louis, MO 
α-Cyano-4-hydroxycinnamic acid Fluka, St. Louis, MO 
Acetonitrile Sigma-Aldrich, St. Louis, MO 
Trifluoroacetic acid Sigma-Aldrich, St. Louis, MO 
Vitek 2 60 instrument Biomérieux, Marcy-l'Etoile, France
Vitek 2 Gram-positive (GP) card Biomérieux, Marcy-l'Etoile, France
Vitek 2 AST-P580 card Biomérieux, Marcy-l'Etoile, France
Vitek 2 Gram-negative (GN) card Biomérieux, Marcy-l'Etoile, France
Vitek 2 AST-N242 card Biomérieux, Marcy-l'Etoile, France
Xpert MRSA Cepheid, Sunnyvale, Ca, USA
GeneXpert IV instrument Cepheid, Sunnyvale, Ca, USA
Microflex LT MALDI-TOF MS instrument Bruker Daltonics, Bremen, Germany
Densitometer Densicheck instrument Biomérieux, Marcy-l'Etoile, France
Catalog Number Comments/Description
NN-2038R
101145
60340
F0507 Flammable, corrosive
70990 Acute toxicity
271004 Flammable, acute toxicity
T6508 Corrosive, acute toxicity
27202
21342
22233
21341
413391
 GXMRSA-100N-10
GXIV-4-D
BDAL microflex LT/SH
27208
